Introduction {#Sec1}
============

Osteoarthritis (OA) is the most common joint disorder affecting increasing numbers of our ageing populations \[[@CR1], [@CR2]\]. Factors contributing to tissue damage include cytokine release, superoxide production and protease activation ultimately leading to loss of joint function \[[@CR3]--[@CR6]\]. Current treatments are largely focused around control of pain and maintenance of function, since there are no effective disease-modifying treatments for OA \[[@CR7]\]. There is therefore an unmet need to gain a deeper understanding of the mechanisms underlying joint destruction in OA.

A number of factors influence ongoing cartilage damage in OA, including injurious mechanical compression of cartilage that alters gene transcription of degradative enzymes including MMPs and aggrecanases (ADAMTSs) \[[@CR8], [@CR9]\]. Such proteases degrade the key extracellular matrix (ECM) components of cartilage including type II collagen and aggrecan \[[@CR10], [@CR11]\]. Several studies have shown increased production of ECM molecules during the early stages of OA \[[@CR12]--[@CR14]\]. Type II collagen, cartilage oligomeric matrix protein (COMP), fibronectin, fibromodulin and tenascin-C are among the ECM proteins that are altered in OA cartilage both at the messenger RNA and protein level. As ongoing protease-mediated cartilage destruction ensues, fragments of ECM proteins are generated, which accumulate during ongoing disease progression.

Recent reports suggest that specific ECM proteins become endogenous catabolic factors potentiating further joint damage in OA. Activation of pro-inflammatory pathways by such ECM proteins has led to their description as damage-associated molecular patterns (DAMPs). Several groups have shown that fragments of ECM proteins acquire novel proteolytic activity upon fragmentation that was hitherto absent in the full-length molecule. For example, a fragment of type II collagen localizing to the N-terminus of the molecule upregulates mRNA and protein levels of MMP-2, MMP-3, MMP-9 and MMP-13 in bovine chondrocytes and explants \[[@CR15]\]. Other ECM molecules showing distinct activity upon fragmentation include fibromodulin, hyaluronan and fibronectin \[[@CR16]--[@CR18]\]. However, it is unclear whether these are the only protein fragments responsible for further cartilage destruction. Tenascin-C (TN-C) is an ECM glycoprotein associated with tissue injury and repair. TN-C is a hexameric protein of 1.5 million Da comprising an assembly domain, epidermal growth factor-like repeats (EGF-L), fibronectin type III repeats (TNIII) and a fibrinogen-like globe (FBG) \[[@CR19]\]. Little TN-C is expressed in normal human joints, but expression is increased in cartilage \[[@CR20], [@CR21]\], synovial tissue \[[@CR22], [@CR23]\] and synovial fluid \[[@CR24]\] in OA and RA. TN-C potentiates chronic inflammation in RA by the upregulation of pro-inflammatory cytokines, and this effect is not observed in TN-C knockout mice \[[@CR25]\]. In contrast, in a murine model of OA, TN-C knockout mice showed evidence of delayed healing and repair \[[@CR26]\]. The increased levels of TN-C reported in OA tissue and the homology of TN-C domains to other known DAMPs in cartilage prompted us to examine whether TN-C fragments exist in arthritic cartilage and whether TN-C fragments possess novel cartilage-degrading ability.

Materials and methods {#Sec2}
=====================

Preparation of human cartilage extracts {#Sec3}
---------------------------------------

Human cartilage samples from patients undergoing joint replacement surgery for OA of the knee/hip or normal cartilage obtained from patients undergoing amputations for trauma were obtained with full Ethics Approval (REC reference number: 09/H0806/45) from St George's and Heatherwood Hospitals NHS Trust. All participants donated tissue with full informed consent. All reagents were obtained from Sigma-Aldrich unless otherwise stated. Human cartilage was washed three times in sterile PBS, and a total of 0.1 g was collected per subject. The cartilage was further dissected in 1 ml of 2 × reducing sample buffer containing 0.2 g SDS, 5 ml upper gel buffer consisting of 84 mM ammediol, 62 mM HCl and 0.02% sodium azide, 1 ml bromophenol blue, 4 ml glycerol and 880 μl of 0.5 M EDTA (pH 8.0) to a final volume of 11 ml. The dissected cartilage and sample buffer were carefully transferred to a 1.5-ml Eppendorf tube and boiled at 100°C for 10 min. The samples were stored at −20°C until further use.

Immunohistochemistry of human cartilage {#Sec4}
---------------------------------------

Fresh cartilage for sectioning was obtained at the time of joint surgery from subjects and immediately fixed in 4% paraformaldehyde in 0.1% phosphate-buffered saline (PBS; pH 7.4) and then sectioned using a cryostat into 7 micron slices onto polylysine-coated glass slides (VWR, Leuven, Belgium). To block endogenous peroxidase activity, 3% H~2~O~2~ was applied in the dark for 15 min. Sections were then blocked with 2% goat serum for 30 min. Following this, sections were incubated with an anti-TN-C monoclonal antibody raised against the N-terminal heptad region of TN-C (MAB 1908, Millipore, Watford, UK) at 1:1,000 for 1 h at room temperature, followed by incubation with Dako REAL EnVision detection system/HRP for rabbit/mouse secondary antibodies for 30 min (Dako, Denmark). For control experiments, a mouse IgG primary antibody (SC-2025) (Santa Cruz, Heidelburg, Germany) was used. Signal was developed with the Dako REAL DAB + chromogen substrate system according to the manufacturers' instructions. Slides were counterstained with haematoxylin and mounted with Histomount (National Diagnostics, Atlanta, USA). All slides were viewed with a Zeiss AXIOPLAN 2 light microscope running on Axiovision system 4.7.

SDS--PAGE and western blotting {#Sec5}
------------------------------

Proteins were resolved by SDS/PAGE with reduction using the ammediol/glycine/HCl buffer system of Wyckoff et al. \[[@CR27]\] for the Tris--glycine buffer method according to Laemmli \[[@CR28]\]. Gels were typically run for 60 min at 200 V.

Staining with Coomassie Brilliant Blue R-250 and silver was performed as previously described \[[@CR29], [@CR30]\]. For western blotting, gels were electrotransferred onto a PVDF membrane at 25 V (constant voltage) for 240 min in 200 ml transfer buffer containing 20% v/v methanol, 7.2 g glycine and 1.512 g Tris base. Five percentage BSA was used for blocking, for 30 min following which the primary anti-TN-C antibody in 1% BSA/TBS for 1 h (dilution 1:1,000). The membrane was washed three times with TBS/0.05% Tween. After washing, a 1:5,000 dilution of an AP-linked secondary antibody (Promega, Southampton, UK) in 1% BSA/TBS was added and incubated for 1 h. Membranes were washed three times in TBS/0.05% Tween and incubated with AP substrate for development for up to 30 min.

Tenascin-C and recombinant TN-C proteins {#Sec6}
----------------------------------------

Full-length tenascin-C (Millipore, Watford, UK) was dialysed into TBS buffer (50 mM Tris--HCl, 150 mM NaCl, pH 7.5) before use in cartilage explant cultures. Recombinant TN-C domains were produced as previously described \[[@CR25]\]. The Limulus amoebocyte lysate (LAL) assay (Cambrex, Wiesbaden, Germany) was used to test the amount of LPS in all purified and recombinant TN-C proteins as previously described \[[@CR25]\]. A standard curve was performed for each experiment using *E.coli*-derived LPS that was provided in the kit. Detection levels for purified proteins were undetectable in the 1--100 pg/ml range, which is well below the levels required to stimulate cartilage degradation.

Measurement of glycosaminoglycan release, aggrecanase and MMP activity {#Sec7}
----------------------------------------------------------------------

Fresh porcine metacarpophalangeal joints of 3- to 9-month-old pigs (Turners', Hampshire, UK) or human tissue were obtained with full Ethical Approval (REC reference number: 09/H0806/45) and dissected into pieces 3 mm × 2--3 mm wide (about 10 mg) as we have previously described \[[@CR31], [@CR33]\]. After dissection, cartilage was rested for 48 h at 37°C under 5% CO~2~ in DMEM containing 5% foetal calf serum, penicillin/streptomycin (100 units/ml), amphotericin B (100 units/ml) and 10 mM HEPES. Each cartilage piece was placed in one well of a round bottom 96-well plate with 200 μl of serum-free medium with full-length TN-C, recombinant TN-C fragments, IL-1α (a gift from Prof J Saklatvala, Imperial College London) as a positive control. Each treatment was performed in triplicate. After 48 h, media and cartilage were harvested and stored at −20°C until use. Each experiment was performed at least 3 times on separate porcine trotters.

The total GAG released into media by cartilage was measured using a modification of the DMMB assay \[[@CR32]\]. A volume of 250 μl of the DMMB assay reagent (16 mg/ml DMMB, 41 mM sodium chloride, 40 mM glycine, 9.5 mM HCl) was added to 2.5 μl of culture medium in a 96-well plate, and then the absorbance was read immediately at 540 nm. Each sample was assayed in duplicate. The optical density from the experimental samples was converted into μg of chondroitin from the standard curve.

Aggrecanase and MMP activity in the conditioned medium of treated cartilage was determined using neoepitope assays as previously described \[[@CR31], [@CR33]\]. Aggrecanase and MMP-specific neoepitope antibodies anti-ARGSV (BC-3) and anti-FFGVG (BC-14), respectively, were kindly provided by Professor Bruce Caterson and Dr Clare Hughes (University of Wales, Cardiff).

Statistics {#Sec8}
----------

The GAG release assay in cartilage explants was evaluated using Graphpad Prism software (San Diego, California). Mean values were calculated for each treatment in triplicate and expressed as mean ± standard error of mean. Significance was analysed with two-tailed Student's *t* tests and defined as *P* \< 0.05.

Results {#Sec9}
=======

Full-length TN-C and TN-C fragments are upregulated in arthritic cartilage {#Sec10}
--------------------------------------------------------------------------

We analysed the expression of full-length TN-C and its fragments in normal human and arthritic cartilage. TN-C protein was detected in its full-length form at \~170 and \~240 kDa, representing the known short and long forms of TN-C (Fig. [1](#Fig1){ref-type="fig"}a). In contrast to normal cartilage, levels of full-length TN-C expression were highly upregulated in cartilage extracts from OA and RA cartilage (lanes 4--12, Fig. [1](#Fig1){ref-type="fig"}a). Two additional forms of TN-C were increased in OA and RA samples and detected at \~100 and \~150 kDa. The results represent true comparisons of equal amounts of protein since equivalent gels as those used for western blotting were stained with Coomassie Brilliant Blue and showed equal protein loading in the specimens (Fig. [1](#Fig1){ref-type="fig"}b). These combined results show that increased expression of full-length TN-C and specific TN-C fragments is found in human arthritic cartilage compared with normal tissue.Fig. 1Western blot analysis of cartilage extracts from patients using an anti-TN-C antibody. A total of 1 μg protein was run per well and membranes developed with alkaline phosphatase (AP) substrate for 1 min each. *Sample identification*: *1* 29 (F), lower leg, amputation; *2* 17 (F), lower limb, osteosarcoma; *3* 45 (M), lower limb, amputation; *4* 72 (M), hip OA; *5* 68 (M), hip OA; *6* 72 (M), knee OA; *7* 75 (F), knee OA; *8* 71 (M), hip OA; *9* 70 (F), knee OA; *10* 66 (F), knee OA; *11* 45 (M), hip, RA; *12* 69 (F), hip, RA. **b** Equivalent samples used as in (**a**) with 1 μg protein per well stained with Coomassie Brilliant *Blue*

Since the anti-TN-C antibody we used recognizes the N-terminal attachment region of TN-C, we could predict the composition of the TN-C fragments detected in our studies of human arthritic cartilage (Fig. [2](#Fig2){ref-type="fig"}). Results show that since the main TN-C fragments we found in cartilage are of molecular weight 100 and 150 kDa, the fragments detected are most likely to comprise of TN-C fragments mapping to the TA + EGF-L + FN type III repeats 1--3 (theoretical molecular mass 97 kDa) and the TA + EGF-L + FN type III repeats 1--8 (theoretical molecular mass 147 kDa).Fig. 2Domain composition of TN-C fragments identified from arthritic cartilage. Human TN-C has a modular structure with repeating units: the TA attachment (heptad) domain at the N-terminus, 14.5 EGF-L repeats, 8--17 FN type III repeats (conserved type III repeats numbered 1--8 are present in all isoforms with splice variants labelled by their designated letter format) and a fibrinogen (FBG) globe at the C-terminus*.* The *table* shows the composition of TN-C fragments isolated from arthritic cartilage in our study

We next confirmed TN-C localization in arthritic cartilage by immunohistochemistry. Our results for TN-C staining in OA cartilage show that TN-C expression was predominantly focused around the superficial and midzones of arthritic human cartilage (Fig. [3](#Fig3){ref-type="fig"}). The highest intensity of TN-C staining was detected primarily within chondrocytes and the pericellular matrix of OA cartilage. An isotype control IgG antibody did not show any positive staining, showing that the staining observed in OA cartilage was specific for TN-C.Fig. 3Distribution of TN-C in human OA cartilage. **a**--**d** are images from 2 OA subjects stained with anti-TN-C antibody. **e**--**h** are the same OA subjects stained with an isotype control IgG mouse antibody. Zones of cartilage are delineated using the following abbreviations---*S* superficial, *M* midzone, *D* deep zone. *Bars* indicate section size of 10 μM or 50 μM

Recombinant TN-C fragments induce glycosaminoglycan release and aggrecanase activity in cartilage {#Sec11}
-------------------------------------------------------------------------------------------------

Since we detected TN-C fragments in arthritic cartilage, we then evaluated the potential for TN-C fragments to induce cartilage degradation. Recombinant fragments comprising the TN-C attachment (TA) domain, the EGF-like (EGF-L) repeats, TN1-5, TN1-3, TN3-5, TN5-7, TN6-8 and the fibrinogen globe (FBG) were cultured with normal porcine articular cartilage (Fig. [4](#Fig4){ref-type="fig"}). Experiments were initially conducted at 1 μM TN-C fragments since this is the active concentration of other ECM DAMPs such as fibronectin fragments that share domain homology with TN-C. The TN-C fragments with greatest statistically significant GAG-releasing activity in porcine articular cartilage were EGF-L, TN3-5, TN5-7, TN6-8 as measured by the DMMB assay (Fig. [4](#Fig4){ref-type="fig"}). The TN-C attachment domain, TN1-3 and the FBG globe did not have statistically significant levels of GAG release. In addition, full-length TN-C also showed no evidence of cartilage degradation. We analysed which enzymes were mediating the GAG release observed by the active TN-C fragments. Figure [4](#Fig4){ref-type="fig"} shows that aggrecanase neoepitope activity was induced by TN-C fragments TN6-8, TN5-7, EGF-like repeats and TN3-5 using the anti-ARGSV antibody that was similar to levels induced by IL-1α. These TN-C fragments showed significant aggrecanase activity compared with medium alone and full-length TN-C. The other TN-C fragments showed no significant increase in aggrecanase activity compared with negative controls. When conditioned medium was tested for cleavage by MMPs using the MMP-cleavage-specific antibody anti-FFGVG, no neoepitope signal was detected in TN-C fragment-treated explants, although cleavage was observed in IL-1α-treated conditioned medium.Fig. 4TN-C fragments induce cartilage degradation in normal articular cartilage. **a** Recombinant TN-C fragments used for cartilage stimulation were run on SDS--PAGE. All proteins were loaded at 1 μg each and stained with silver. **b** TN-C fragments at 1 μM were used to stimulate porcine cartilage explants for 2 days. The culture medium was harvested and tested for the presence of GAG using the DMMB dye assay (*n* = 3). **c**, **d** Equal volumes of conditioned media (50 μl) from the experiment shown in **b** were deglycosylated and western blots performed for aggrecanase-cleaved neoepitopes using the BC-3 antibody (**c**) and the BC-14 antibody (**d**). Loading controls were medium alone, **c**, used as a negative control and IL-1α, which served as a positive control

We then tested the dose--response effect of active recombinant TN-C fragments in normal porcine and human articular cartilage. We found that the active fragments maintained their GAG-releasing activity over the micromolar range, with the most significant activity observed at 0.1 and 1 μM concentrations (Fig. [5](#Fig5){ref-type="fig"}a). The GAG release assay showed that the highest levels of cartilage degradation were induced by the EGF-L repeats and TN6-8 in the 0.01--1 μM range. In experiments with normal human articular cartilage (obtained from a 69-year-old subject who underwent joint replacement for a fractured neck of femur), we found that the same TN-C fragments that were active in porcine articular cartilage also had GAG-releasing activity in the micromolar range in normal cartilage (Fig. [5](#Fig5){ref-type="fig"}b). It was also noted that differences in total GAG release between experiments in Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} were found, which are most likely due to natural variation in glycosaminoglycan release between different cartilage explants.Fig. 5**a** Porcine cartilage was stimulated with recombinant TN-C fragments with a concentration range of 0.01--1 μM. After 2 days, conditioned medium was harvested and GAG release measured using the DMMB assay (*n* = 3). **b** Normal human cartilage (obtained from a 69-year-old subject with a femoral neck fracture) was stimulated with recombinant TN-C fragments at 1 μM each. Conditioned medium was harvested after 2 days and GAG release measured using the DMMB assay (*n* = 3)

Discussion {#Sec12}
==========

In this study, we have shown that two main forms of fragmented TN-C of 100 kDa and 150 kDa are detectable in arthritic cartilage but not in normal subjects. The TN-C fragments we have detected map to the EGF-L and FN type III 3--8 domains in arthritic human cartilage. Recombinant TN-C fragments comprising the same domains induce GAG release and aggrecanase activity in cartilage in a dose-dependent manner. Although increased TN-C expression has previously been described in arthritic cartilage \[[@CR20], [@CR21], [@CR34]\], our study is the first to describe and characterize TN-C fragments in cartilage. Zhen et al. \[[@CR35]\] recently showed that human cartilage subjected to digestion with ADAMTS-5 cleaves TN-C peptides that map to the N-terminal TA domain when digested cartilage was analysed by mass spectrometry. It is therefore plausible that the generation of TN-C fragments by proteases such as ADAMTS-5 generates TN-C fragments which then stimulate a positive feedback loop of further cartilage matrix degradation mediated by protease activation including aggrecanases as found in our study.

Work conducted in other tissues has shown that leg ulcer exudates have high levels of TN-C fragments \[[@CR36]\] and the EGF-L repeats are increased in blood vessels of subjects undergoing carotid endarterectomy \[[@CR37]\]. Specific TN-C fragments have distinct functions: the EGF-L domains influence neuronal migration in development \[[@CR38], [@CR39]\] and induce apoptosis in smooth muscle cells \[[@CR36]\]. The FN III domains of TN-C are susceptible to proteolytic cleavage \[[@CR40]\] and interact with ligands including integrins \[[@CR41]\], heparin binding \[[@CR42]\] and binding to other ECM molecules including fibronectin \[[@CR43]\]. Whereas previous work has shown that full-length TN-C is involved in wound repair in OA \[[@CR26], [@CR34]\], our work has shown that when TN-C is cleaved to generate fragmented forms, such TN-C fragments acquire novel proteolytic activity that mediates catabolic pathways in articular cartilage. There are therefore differences between the full-length and fragmented forms of TN-C, which mediate anabolic and catabolic pathways, respectively, in OA models.

Based on our findings and those of other groups, we propose a scheme whereby a balance between anabolic effects and catabolic effects mediated by TN-C fragments and other ECM protein fragments occur in the OA joint (Fig. [6](#Fig6){ref-type="fig"}). Future work will be required to establish pathways of activation induced by the active TN-C fragments we have identified. It is possible that TN-C fragments such as those we have identified engage with existing receptors in the OA joint, including syndecans \[[@CR44]\], integrins \[[@CR45]\] or toll-like receptors \[[@CR46]\]. Alternatively, it is possible that specific forms of TN-C may inhibit aggrecanase activity, as described in the case of the C-terminal region of fibronectin with ADAMTS-4 \[[@CR47]\].Fig. 6Scheme for role of TN-C and TN-C fragments in OA pathology
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